In Vitro Screening Methods To Assess the Potential of In Vivo Precipitation of Injectable Formulations upon Intravenous Administration

References

1. 1.↵
   1. Yalkowski S. H.

   1. Yalkowski S. H.,
   2. Roseman T. J.

   Chapter 3. Solubilization of Drugs by Cosolvents. In Techniques of Solubilization of Drugs; Yalkowski S. H., Ed.; Marcel Dekker: New York, 1981.
2. 2.↵
   1. Schroeder H. G.,
   2. DeLuca P. P.

   A study on the in vivo precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenter. Drug Assoc. 1974, 28 (1), 1–14.

   OpenUrlPubMed
3. 3.↵
   1. Yalkowski S. H.,
   2. Valvani S. C.,
   3. Johnson B. W.

   In vitro method for detecting precipitation of parenteral formulations after injection. J. Pharm. Sci. 1983, 72 (9), 1014–1017.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Yalkowski S. H.

   1. Repta A. J.

   Chapter 4. Alteration of Apparent Solubility through Complexation. In Techniques of Solubilization of Drugs; Yalkowski S. H., Ed.; Marcel Dekker: New York, 1981.
5. 5.↵
   1. Davio S. R.,
   2. Mc Shane M. M.,
   3. Kakuk T. J.,
   4. Zaya R. M.,
   5. Cole S L.

   Precipitation of the rennin inhibitor ditekiren upon IV infusion; in vitro studies and their relationship to in vivo precipitation in the Cynomolgus monkey. Pharm. Res. 1991, 8 (1), 80–83.

   OpenUrlPubMed
6. 6.↵
   1. Greenfield J. C.,
   2. Loux S. J.,
   3. Sood V. K.,
   4. Jenkins K. M.,
   5. Davio S. M.

   In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel rennin inhibitor pseudopeptide. Pharm. Res. 1991, 8 (4), 475–479.

   OpenUrlPubMed
7. 7.↵
   1. Cox J. W.,
   2. Sage G. P.,
   3. Wynalda M. A.,
   4. Ulrich R. G.,
   5. Larson P. G.,
   6. Su C. C.

   Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J. Pharm. Sci. 1991, 80 (4), 371–375.

   OpenUrlPubMed
8. 8.↵
   1. Myrdal P. B.,
   2. Simamora P.,
   3. Surakitbanharn Y.,
   4. Yalkowski S. H.

   Studies in phlebitis. VII: In vitro and in vivo evaluation of pH solubilized levenmopamil. J. Pharm. Sci. 1995, 84 (7), 849–852.

   OpenUrlPubMedWeb of Science
9. 9.↵
   1. Simamora P.,
   2. Pinsuwan S.,
   3. Surakitbanham Y.,
   4. Yalkowski S. H.

   Studies in phlebitis. VIII: Evaluations of pH solubilized intravenous dexverapamil formulations. PDA J. Pharm. Sci. Technol. 1996, 50 (2), 123–128.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Johnson J. L. H.,
    2. Yalkowsky S. H.

    Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength. AAPS PharmSciTech 2006, 7 (1), E1–E5.

    OpenUrlPubMed
11. 11.↵
    1. Jencks W. P.

    Catalysis in Chemistry and Enzymology; Mc-Graw Hill: New York, 1969; pp 358–392.
12. 12.↵
    1. Yalkowski S. H.,
    2. Krzyzaniak J. F.,
    3. Ward G. H.

    Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7), 787–796.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Portmann G. A.,
    2. Simmons D. M.

    Microscopic determination of drug solubility in plasma and calculation of injection rates with a plasma circulatory model to prevent precipitation on intravenous injection. J. Pharm. Biomed. Anal. 1995, 13 (9), 1189–1193.

    OpenUrlPubMed
14. 14.↵
    1. Johnson J. L. H.,
    2. He Y.,
    3. Yalkowsky S. H.

    Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J. Pharm. Sci. 2003, 92 (8), 1574–1581.

    OpenUrlPubMed
15. 15.↵
    1. Ward G. H.,
    2. Yalkowsky S. H.

    The role of effective concentration in interpreting hemolysis data. J. Parenter. Sci. Technol. 1992, 46 (5), 161–162.

    OpenUrlPubMed
16. 16.↵
    1. Rubino J. T.,
    2. Nellore R.,
    3. Parmar B.

    Dynamic compatibility testing of DMP 840, and experimental antitumor agent. PDA J. Pharm. Sci. Technol. 1997, 51 (3), 130–136.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Olson W. P.,
    2. Faith M. R.

    Human serum albumin as a cosolvent for parenteral drugs. J. Parenter. Sci. Technol. 1988, 42 (3), 82–85.

    OpenUrlPubMed
18. 18.↵
    1. Swarbrick J.,
    2. Boylan J. C.

    1. Rodriguez-Hornedo N.

    Crystallization and the properties of crystals. In Encyclopedia of Pharmaceutical Technology, V3; Swarbrick J., Boylan J. C., Eds.; Marcel Dekker: New York, 1992; pp 399–434.
19. 19.↵
    1. Ziller K. H.,
    2. Rupprecht H. H.

    Control of crystal growth in drug suspensions. Part 2. Influence of polymers on dissolution and crystallization during temperature cycling. Pharm. Ind. 1990, 52, 1017–1022.

    OpenUrl
20. 20.↵
    1. Bittner B.,
    2. Mountfield R. J.

    Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Devel. 2002, 5 (1), 59–71.

    OpenUrlPubMed
21. 21.↵
    1. Alvarez-Nunez F. A.,
    2. Yalkowsky S. H.

    Buffer capacity and precipitation control of pH solubilized phenytoin formulations. Int. J. Pharm. 1999, 185 (1), 45–49.

    OpenUrlPubMed
22. 22.↵
    1. Li P.,
    2. Rao V.,
    3. Tabibi S. E.,
    4. Yalkowsky S. H.

    Evaluation of in vitro precipitation methods. J. Pharm. Sci. 1998, 87 (2), 196–199.

    OpenUrlPubMed
23. 23.↵
    1. Narazaki R.,
    2. Sanghvi R.,
    3. Yalkowsky S. H.

    Estimation of drug precipitation upon dilution of pH-controlled formulations. Mol. Pharm. 2007, 4 (4), 550–555.

    OpenUrlPubMed